SuperworthGRI Bio EPS GRI
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$51.69
- Latest quarter, Q2 FY26
- −$0.91
- Fiscal year 2025
- −$248.19
GRI Bio's earnings per share was −$51.69 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.91.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$248.19 | n/a |
| FY2024 | −$5101.99 | n/a |
| FY2022 | −$691323.36 | n/a |
| FY2021 | −$1858256.40 | n/a |
| FY2020 | −$1390443.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.91 | n/a | −$51.69 | |
| Q1 FY26 | −$1.61 | n/a | −$87.50 | |
| Q4 FY25 | −$13.33 | n/a | −$248.19 | |
| Q3 FY25 | −$35.84 | n/a | −$455.89 | |
| Q2 FY25 | −$36.72 | n/a | −$739.81 | |
| Q1 FY25 | −$162.30 | n/a | −$2434.89 | |
| Q4 FY24 | −$221.03 | n/a | −$5101.99 | |
| Q3 FY24 | −$319.76 | n/a | n/a | |
| Q2 FY24 | −$1731.80 | n/a | n/a | |
| Q1 FY24 | −$2829.40 | n/a | n/a | |
| Q3 FY23 | −$31311.28 | n/a | −$394256.52 | |
| Q2 FY23 | −$113940.12 | n/a | −$379838.48 |
Against its peers
Companies in Healthcare nearest GRI Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GRIGRI Bio | −$51.69 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on GRI Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.